{"id":"NCT00190684","sponsor":"Eli Lilly and Company","briefTitle":"Long-Term, Open Label Atomoxetine Study","officialTitle":"Long-Term, Open Label Safety Study of Atomoxetine Hydrochloride in Patients, 6 Years and Older With Attention-Deficit/Hyperactivity Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2000-08","primaryCompletion":"2009-10","completion":"2009-10","firstPosted":"2005-09-19","resultsPosted":"2011-01-17","lastUpdate":"2011-01-17"},"enrollment":1553,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Attention Deficit Hyperactivity Disorder"],"interventions":[{"type":"DRUG","name":"atomoxetine","otherNames":["LY139603","Strattera"]}],"arms":[{"label":"Atomoxetine","type":"EXPERIMENTAL"}],"summary":"To learn about the safety and any side effects of atomoxetine when given to children and adolescents for about 5 years (long-term) and to learn whether atomoxetine can help children and adolescents with attention-deficit/hyperactivity disorder (ADHD) who take the drug for about 5 years (long-term).\n\nStudy participants can be atomoxetine naive, atomoxetine experienced whose therapy has been interrupted or, atomoxetine experienced on a known stable dose.","primaryOutcome":{"measure":"Categorical Changes in Vital Signs (Blood Pressure [BP], Pulse, Weight, Temperature) During the Study","timeFrame":"Baseline through 5 years","effectByArm":[{"arm":"Atomoxetine","deltaMin":228,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":100,"countries":["United States","Australia","Belgium","Canada","France","Germany","Israel","Italy","Netherlands","Norway","Puerto Rico","South Africa","Sweden","United Kingdom"]},"refs":{"pmids":["17242628"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":92,"n":1551},"commonTop":["Headache","Nasopharyngitis","Cough","Vomiting","Pharyngolaryngeal pain"]}}